Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.

Stolz LE, Horn PT.

Drugs Today (Barc). 2010 Aug;46(8):547-55. doi: 10.1358/dot.2010.46.8.1507205. Review.

PMID:
20830315
2.

Ecallantide for treatment of acute attacks of hereditary angioedema.

Martello JL, Woytowish MR, Chambers H.

Am J Health Syst Pharm. 2012 Apr 15;69(8):651-7. doi: 10.2146/ajhp110227. Review.

PMID:
22472866
3.

Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.

Stolz LE, Sheffer AL.

Expert Rev Clin Immunol. 2012 Jan;8(1):25-32. doi: 10.1586/eci.11.81.

PMID:
22149337
4.

Use of ecallantide in pediatric hereditary angioedema.

MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R.

Pediatrics. 2013 Aug;132(2):e490-7. doi: 10.1542/peds.2013-0646. Epub 2013 Jul 22.

5.

Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.

Craig TJ, Li HH, Riedl M, Bernstein JA, Lumry WR, MacGinnitie AJ, Stolz LE, Biedenkapp J, Chyung Y.

J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):206-212.e4. doi: 10.1016/j.jaip.2014.09.001. Epub 2014 Oct 29.

6.

Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.

MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):178-85. doi: 10.2500/aap.2012.33.3528.

PMID:
22525395
7.

Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.

Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T.

J Allergy Clin Immunol. 2007 Aug;120(2):416-22. Epub 2007 Jun 7.

PMID:
17559913
8.

Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.

Bernstein JA, Qazi M.

Expert Rev Clin Immunol. 2010 Jan;6(1):29-39. Review.

PMID:
20383888
9.

Ecallantide: in acute hereditary angioedema.

Garnock-Jones KP.

Drugs. 2010 Jul 30;70(11):1423-31. doi: 10.2165/11205850-000000000-00000. Review.

PMID:
20614949
10.

Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.

Banta E, Horn P, Craig TJ.

Allergy Asthma Proc. 2011 Jul-Aug;32(4):319-24. doi: 10.2500/aap.2011.32.3440.

PMID:
21781409
11.

Management of acute attacks of hereditary angioedema: role of ecallantide.

Duffey H, Firszt R.

J Blood Med. 2015 Apr 16;6:115-23. doi: 10.2147/JBM.S66825. eCollection 2015. Review.

12.

Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.

Lumry WR, Bernstein JA, Li HH, MacGinnitie AJ, Riedl M, Soteres DF, Craig TJ, Campion M, Iarrobino R, Stolz LE, Pullman WE.

Allergy Asthma Proc. 2013 Mar-Apr;34(2):155-61. doi: 10.2500/aap.2013.34.3653. Erratum in: Allergy Asthma Proc. 2013 May-Jun;34(3):291.

PMID:
23484891
13.

Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.

Bernstein JA, Shea EP, Koester J, Iarrobino R, Pullman WE.

Allergy. 2012 Sep;67(9):1173-80. doi: 10.1111/j.1398-9995.2012.02864.x. Epub 2012 Jul 5.

14.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Jun;104(6):523-9. doi: 10.1016/j.anai.2010.04.012.

PMID:
20568386
15.

Response time for ecallantide treatment of acute hereditary angioedema attacks.

Riedl M, Campion M, Horn PT, Pullman WE.

Ann Allergy Asthma Immunol. 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005. Epub 2010 Oct 25.

PMID:
21130380
16.

Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.

Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):184-188.e2. doi: 10.1016/j.anai.2012.12.007. Epub 2013 Jan 5.

PMID:
23548529
17.

Ecallantide for the treatment of hereditary angiodema in adults.

Lunn M, Banta E.

Clin Med Insights Cardiol. 2011;5:49-54. doi: 10.4137/CMC.S4434. Epub 2011 May 17.

18.

Management and prevention of hereditary angioedema attacks.

Lumry WR.

Am J Manag Care. 2013 Jun;19(7 Suppl):s111-8.

19.

Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.

Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA.

Ann Allergy Asthma Immunol. 2013 Mar;110(3):168-72. doi: 10.1016/j.anai.2012.12.004. Epub 2013 Jan 8.

PMID:
23548526
20.

Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.

Wu MA, Zanichelli A, Mansi M, Cicardi M.

Expert Opin Pharmacother. 2016;17(1):27-40. doi: 10.1517/14656566.2016.1104300. Epub 2015 Oct 29. Review.

PMID:
26512744

Supplemental Content

Support Center